Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site

Hitoshi Kusaba, Yoshihiro Shibata, Shuji Arita, hiroshi ariyama, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP) has demonstrated activities in various malignancies, including head and neck, lung, esophageal, gastric, and pancreatic cancers. We reviewed our experience of 11 patients diagnosed as carcinoma of unknown primary site (CUPS), who were treated with infusional 5-FU and CDDP between January 1998 and December 2005. The median number of cycles administered was three (range: 1-12). All patients had measurable disease. Six partial responses were obtained (response rate: 54.5%, 95% confidence interval: 23.4-83.3%). The median survival time for all patients was 10 mo (range, 2-37 mo). The median time to disease progression was 3 mo (range, 1-6 mo). This regimen was well tolerated, with grade 3-4 neutropenia (two patients), febrile neutropenia (one patient), grade 3 nausea/vomiting (one patient), and grade 3 stomatitis (two patients). Grade 2 leukoencephalopathy was observed in one patient. No treatment-related death was observed. The combination chemotherapy of infusional 5-FU and CDDP was feasible and tolerated with promising activity for CUPS.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalMedical Oncology
Volume24
Issue number2
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Fluorouracil
Cisplatin
Carcinoma
Drug Therapy
Combination Drug Therapy
Leukoencephalopathies
Febrile Neutropenia
Stomatitis
Esophageal Neoplasms
Head and Neck Neoplasms
Neutropenia
Pancreatic Neoplasms
Nausea
Stomach Neoplasms
Vomiting
Disease Progression
Lung Neoplasms
Confidence Intervals
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site. / Kusaba, Hitoshi; Shibata, Yoshihiro; Arita, Shuji; ariyama, hiroshi; Baba, Eishi; Mitsugi, Kenji; Harada, Mine; Nakano, Shuji.

In: Medical Oncology, Vol. 24, No. 2, 01.06.2007, p. 259-264.

Research output: Contribution to journalArticle

Kusaba, Hitoshi ; Shibata, Yoshihiro ; Arita, Shuji ; ariyama, hiroshi ; Baba, Eishi ; Mitsugi, Kenji ; Harada, Mine ; Nakano, Shuji. / Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site. In: Medical Oncology. 2007 ; Vol. 24, No. 2. pp. 259-264.
@article{f1a9375de5414d4a9aa463c4c3e6e5f3,
title = "Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site",
abstract = "A combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP) has demonstrated activities in various malignancies, including head and neck, lung, esophageal, gastric, and pancreatic cancers. We reviewed our experience of 11 patients diagnosed as carcinoma of unknown primary site (CUPS), who were treated with infusional 5-FU and CDDP between January 1998 and December 2005. The median number of cycles administered was three (range: 1-12). All patients had measurable disease. Six partial responses were obtained (response rate: 54.5{\%}, 95{\%} confidence interval: 23.4-83.3{\%}). The median survival time for all patients was 10 mo (range, 2-37 mo). The median time to disease progression was 3 mo (range, 1-6 mo). This regimen was well tolerated, with grade 3-4 neutropenia (two patients), febrile neutropenia (one patient), grade 3 nausea/vomiting (one patient), and grade 3 stomatitis (two patients). Grade 2 leukoencephalopathy was observed in one patient. No treatment-related death was observed. The combination chemotherapy of infusional 5-FU and CDDP was feasible and tolerated with promising activity for CUPS.",
author = "Hitoshi Kusaba and Yoshihiro Shibata and Shuji Arita and hiroshi ariyama and Eishi Baba and Kenji Mitsugi and Mine Harada and Shuji Nakano",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/BF02698049",
language = "English",
volume = "24",
pages = "259--264",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site

AU - Kusaba, Hitoshi

AU - Shibata, Yoshihiro

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Baba, Eishi

AU - Mitsugi, Kenji

AU - Harada, Mine

AU - Nakano, Shuji

PY - 2007/6/1

Y1 - 2007/6/1

N2 - A combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP) has demonstrated activities in various malignancies, including head and neck, lung, esophageal, gastric, and pancreatic cancers. We reviewed our experience of 11 patients diagnosed as carcinoma of unknown primary site (CUPS), who were treated with infusional 5-FU and CDDP between January 1998 and December 2005. The median number of cycles administered was three (range: 1-12). All patients had measurable disease. Six partial responses were obtained (response rate: 54.5%, 95% confidence interval: 23.4-83.3%). The median survival time for all patients was 10 mo (range, 2-37 mo). The median time to disease progression was 3 mo (range, 1-6 mo). This regimen was well tolerated, with grade 3-4 neutropenia (two patients), febrile neutropenia (one patient), grade 3 nausea/vomiting (one patient), and grade 3 stomatitis (two patients). Grade 2 leukoencephalopathy was observed in one patient. No treatment-related death was observed. The combination chemotherapy of infusional 5-FU and CDDP was feasible and tolerated with promising activity for CUPS.

AB - A combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP) has demonstrated activities in various malignancies, including head and neck, lung, esophageal, gastric, and pancreatic cancers. We reviewed our experience of 11 patients diagnosed as carcinoma of unknown primary site (CUPS), who were treated with infusional 5-FU and CDDP between January 1998 and December 2005. The median number of cycles administered was three (range: 1-12). All patients had measurable disease. Six partial responses were obtained (response rate: 54.5%, 95% confidence interval: 23.4-83.3%). The median survival time for all patients was 10 mo (range, 2-37 mo). The median time to disease progression was 3 mo (range, 1-6 mo). This regimen was well tolerated, with grade 3-4 neutropenia (two patients), febrile neutropenia (one patient), grade 3 nausea/vomiting (one patient), and grade 3 stomatitis (two patients). Grade 2 leukoencephalopathy was observed in one patient. No treatment-related death was observed. The combination chemotherapy of infusional 5-FU and CDDP was feasible and tolerated with promising activity for CUPS.

UR - http://www.scopus.com/inward/record.url?scp=36248973676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248973676&partnerID=8YFLogxK

U2 - 10.1007/BF02698049

DO - 10.1007/BF02698049

M3 - Article

VL - 24

SP - 259

EP - 264

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -